Increased risk of breast cancer in neurofibromatosis type 1: current insights

Sacha J Howell,1 Kimberley Hockenhull,1 Zena Salih,1 D Gareth Evans2,3 1Department of Medical Oncology, The Christie NHS Foundation Trust, 2Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Howell SJ, Hockenhull K, Salih Z, Evans DG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	breast cancer neurofibromatosis type 1 NF1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/75c4d60e51694ff9a58977caa5effda3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75c4d60e51694ff9a58977caa5effda3
record_format	dspace
spelling	oai:doaj.org-article:75c4d60e51694ff9a58977caa5effda32021-12-02T04:39:05ZIncreased risk of breast cancer in neurofibromatosis type 1: current insights1179-1314https://doaj.org/article/75c4d60e51694ff9a58977caa5effda32017-08-01T00:00:00Zhttps://www.dovepress.com/increased-risk-of-breast-cancer-in-neurofibromatosis-type-1-current-in-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Sacha J Howell,1 Kimberley Hockenhull,1 Zena Salih,1 D Gareth Evans2,3 1Department of Medical Oncology, The Christie NHS Foundation Trust, 2Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, 3Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Abstract: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by mutation/deletion of the NF1 gene. The gene product, neurofibromin, is a tumor suppressor which represses the activity of the Ras oncogene. Central nervous system (CNS) tumors have long been associated with NF1, but their association with several other malignancies has been demonstrated. In this review, we summarize the epidemiological data that irrefutably support a link between NF1 and an increased risk of early-onset breast cancer, to levels at which annual mammography is currently recommended in national high-risk screening programs. We discuss the reasons for the observed adverse breast cancer prognosis in NF1 cases, including late presentation and more aggressive tumor subtypes, and recommend that a collaborative breast screening study be initiated to better serve this currently underserved population of women. Keywords: breast cancer, neurofibromatosis type 1, NF1Howell SJHockenhull KSalih ZEvans DGDove Medical Pressarticlebreast cancerneurofibromatosis type 1NF1Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 531-536 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer neurofibromatosis type 1 NF1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer neurofibromatosis type 1 NF1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Howell SJ Hockenhull K Salih Z Evans DG Increased risk of breast cancer in neurofibromatosis type 1: current insights
description	Sacha J Howell,1 Kimberley Hockenhull,1 Zena Salih,1 D Gareth Evans2,3 1Department of Medical Oncology, The Christie NHS Foundation Trust, 2Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, 3Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Abstract: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by mutation/deletion of the NF1 gene. The gene product, neurofibromin, is a tumor suppressor which represses the activity of the Ras oncogene. Central nervous system (CNS) tumors have long been associated with NF1, but their association with several other malignancies has been demonstrated. In this review, we summarize the epidemiological data that irrefutably support a link between NF1 and an increased risk of early-onset breast cancer, to levels at which annual mammography is currently recommended in national high-risk screening programs. We discuss the reasons for the observed adverse breast cancer prognosis in NF1 cases, including late presentation and more aggressive tumor subtypes, and recommend that a collaborative breast screening study be initiated to better serve this currently underserved population of women. Keywords: breast cancer, neurofibromatosis type 1, NF1
format	article
author	Howell SJ Hockenhull K Salih Z Evans DG
author_facet	Howell SJ Hockenhull K Salih Z Evans DG
author_sort	Howell SJ
title	Increased risk of breast cancer in neurofibromatosis type 1: current insights
title_short	Increased risk of breast cancer in neurofibromatosis type 1: current insights
title_full	Increased risk of breast cancer in neurofibromatosis type 1: current insights
title_fullStr	Increased risk of breast cancer in neurofibromatosis type 1: current insights
title_full_unstemmed	Increased risk of breast cancer in neurofibromatosis type 1: current insights
title_sort	increased risk of breast cancer in neurofibromatosis type 1: current insights
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/75c4d60e51694ff9a58977caa5effda3
work_keys_str_mv	AT howellsj increasedriskofbreastcancerinneurofibromatosistype1currentinsights AT hockenhullk increasedriskofbreastcancerinneurofibromatosistype1currentinsights AT salihz increasedriskofbreastcancerinneurofibromatosistype1currentinsights AT evansdg increasedriskofbreastcancerinneurofibromatosistype1currentinsights
_version_	1718401127879278592

Increased risk of breast cancer in neurofibromatosis type 1: current insights

Ejemplares similares